Does the media prefer NMRA or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 17 more articles in the media than Neumora Therapeutics. MarketBeat recorded 22 mentions for Eyepoint Pharmaceuticals and 5 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Eyepoint Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NMRA or CALT?

Neumora Therapeutics currently has a consensus target price of $6.57, indicating a potential upside of 310.71%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to NMRA or CRON?

In the previous week, Neumora Therapeutics had 2 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Neumora Therapeutics and 3 mentions for Cronos Group. Neumora Therapeutics' average media sentiment score of 1.87 beat Cronos Group's score of 1.59 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cronos Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, ANRO or NMRA?

Alto Neuroscience is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A

Is ANRO or NMRA more profitable?

Alto Neuroscience's return on equity of -46.46% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -46.46% -39.09% Neumora Therapeutics N/A -181.70% -119.15%

Does the media favor ANRO or NMRA?

In the previous week, Alto Neuroscience had 8 more articles in the media than Neumora Therapeutics. MarketBeat recorded 13 mentions for Alto Neuroscience and 5 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Alto Neuroscience's score of 0.66 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer NMRA or PCRX?

In the previous week, Pacira BioSciences had 15 more articles in the media than Neumora Therapeutics. MarketBeat recorded 20 mentions for Pacira BioSciences and 5 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Pacira BioSciences' score of 0.78 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pacira BioSciences 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Neumora Therapeutics (NMRA) Competitors

$1.60 -0.13 (-7.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 0.00 (0.00%)

As of 07:34 PM Eastern

Compare

NMRA vs. EYPT, CALT, CRON, ANRO, and PCRX

Should you buy Neumora Therapeutics stock or one of its competitors? Neumora Therapeutics's main competitors and comparable companies include Eyepoint Pharmaceuticals (EYPT), Calliditas Therapeutics AB (publ) (CALT), Cronos Group (CRON), Alto Neuroscience (ANRO), and Pacira BioSciences (PCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neumora Therapeutics compare to Eyepoint Pharmaceuticals?

Neumora Therapeutics (NASDAQ:NMRA) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 310.71%. Eyepoint Pharmaceuticals has a consensus target price of $44.38, suggesting a potential upside of 200.85%. Given Neumora Therapeutics' higher probable upside, equities analysts clearly believe Neumora Therapeutics is more favorable than Eyepoint Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Eyepoint Pharmaceuticals had 17 more articles in the media than Neumora Therapeutics. MarketBeat recorded 22 mentions for Eyepoint Pharmaceuticals and 5 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Eyepoint Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neumora Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

Eyepoint Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Eyepoint Pharmaceuticals	$31.37M	40.54	-$231.96M	-$3.74	N/A

Neumora Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Eyepoint Pharmaceuticals beats Neumora Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Neumora Therapeutics (NASDAQ:NMRA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Neumora Therapeutics currently has a consensus target price of $6.57, indicating a potential upside of 310.71%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Neumora Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neumora Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Neumora Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Neumora Therapeutics' return on equity of -181.70% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

In the previous week, Neumora Therapeutics had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Neumora Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Neumora Therapeutics' average media sentiment score of 1.87 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Very Positive
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Neumora Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

Neumora Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Cronos Group?

Neumora Therapeutics (NASDAQ:NMRA) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cronos Group has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Cronos Group	$146.59M	7.94	-$9.45M	$0.20	15.70

Neumora Therapeutics has a beta of 2.75, suggesting that its share price is 175% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Cronos Group has a net margin of 39.08% compared to Neumora Therapeutics' net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Cronos Group	39.08%	4.85%	4.62%

In the previous week, Neumora Therapeutics had 2 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Neumora Therapeutics and 3 mentions for Cronos Group. Neumora Therapeutics' average media sentiment score of 1.87 beat Cronos Group's score of 1.59 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 310.71%. Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 26.75%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Neumora Therapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cronos Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Neumora Therapeutics beats Cronos Group on 9 of the 16 factors compared between the two stocks.

How does Neumora Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Alto Neuroscience's return on equity of -46.46% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Neumora Therapeutics	N/A	-181.70%	-119.15%

In the previous week, Alto Neuroscience had 8 more articles in the media than Neumora Therapeutics. MarketBeat recorded 13 mentions for Alto Neuroscience and 5 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Alto Neuroscience's score of 0.66 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alto Neuroscience has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market.

Alto Neuroscience is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

47.7% of Neumora Therapeutics shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alto Neuroscience currently has a consensus target price of $36.63, suggesting a potential upside of 13.96%. Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 310.71%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Neumora Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Neumora Therapeutics compare to Pacira BioSciences?

Neumora Therapeutics (NASDAQ:NMRA) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Pacira BioSciences had 15 more articles in the media than Neumora Therapeutics. MarketBeat recorded 20 mentions for Pacira BioSciences and 5 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Pacira BioSciences' score of 0.78 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pacira BioSciences	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has higher revenue and earnings than Neumora Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Pacira BioSciences	$746.16M	1.23	$7.03M	$0.35	65.71

Pacira BioSciences has a net margin of 1.96% compared to Neumora Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Pacira BioSciences	1.96%	9.68%	5.30%

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neumora Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Neumora Therapeutics presently has a consensus price target of $6.57, indicating a potential upside of 310.71%. Pacira BioSciences has a consensus price target of $29.80, indicating a potential upside of 29.57%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Pacira BioSciences beats Neumora Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$320.54M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-1.20	775.15	269.06	25.28
Price / Sales	N/A	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	2.58	11.60	12.91	6.24
Net Income	-$236.93M	$2.77B	$3.45B	$347.60M
7 Day Performance	-1.84%	0.17%	1.12%	1.07%
1 Month Performance	1.27%	0.35%	1.79%	1.03%
1 Year Performance	1.27%	161.52%	67.69%	20.77%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	3.2253 of 5 stars	$1.60 -7.5%	$6.57 +310.7%	+10.9%	$320.54M	N/A	N/A	108	News Coverage Earnings Report
EYPT Eyepoint Pharmaceuticals	2.3648 of 5 stars	$13.07 -5.9%	$44.38 +239.5%	+22.4%	$1.20B	$31.37M	N/A	120	Options Volume Gap Up
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
CRON Cronos Group	1.6677 of 5 stars	$3.00 -3.2%	$2.30 -23.3%	+20.6%	$1.15B	$146.59M	15.00	450	Positive News Analyst Upgrade
ANRO Alto Neuroscience	1.5175 of 5 stars	$28.29 -1.3%	$35.25 +24.6%	+945.7%	$1.01B	N/A	N/A	N/A	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. EYPT, CALT, CRON, ANRO, and PCRX

How does Neumora Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Neumora Therapeutics compare to Cronos Group?

Summary

How does Neumora Therapeutics compare to Alto Neuroscience?

Summary

How does Neumora Therapeutics compare to Pacira BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. EYPT, CALT, CRON, ANRO, and PCRX

How does Neumora Therapeutics compare to Eyepoint Pharmaceuticals?

Do analysts prefer NMRA or EYPT?

Does the media prefer NMRA or EYPT?

Which has more risk & volatility, NMRA or EYPT?

Which has preferable earnings and valuation, NMRA or EYPT?

Is NMRA or EYPT more profitable?

Do insiders & institutionals hold more shares of NMRA or EYPT?

Summary

How does Neumora Therapeutics compare to Calliditas Therapeutics AB (publ)?

Do insiders & institutionals have more ownership in NMRA or CALT?

Do analysts rate NMRA or CALT?

Which has more volatility and risk, NMRA or CALT?

Is NMRA or CALT more profitable?

Does the media refer more to NMRA or CALT?

Which has preferable valuation and earnings, NMRA or CALT?

Summary

How does Neumora Therapeutics compare to Cronos Group?

Do institutionals and insiders hold more shares of NMRA or CRON?

Which has preferable valuation and earnings, NMRA or CRON?

Which has more volatility and risk, NMRA or CRON?

Is NMRA or CRON more profitable?

Does the media refer more to NMRA or CRON?

Do analysts recommend NMRA or CRON?

Summary

How does Neumora Therapeutics compare to Alto Neuroscience?

Is ANRO or NMRA more profitable?

Does the media favor ANRO or NMRA?

Which has more volatility and risk, ANRO or NMRA?

Which has higher valuation & earnings, ANRO or NMRA?

Do institutionals & insiders hold more shares of ANRO or NMRA?

Do analysts prefer ANRO or NMRA?

Summary

How does Neumora Therapeutics compare to Pacira BioSciences?

Does the media prefer NMRA or PCRX?

Which has higher valuation and earnings, NMRA or PCRX?

Is NMRA or PCRX more profitable?

Do insiders & institutionals believe in NMRA or PCRX?

Which has more volatility & risk, NMRA or PCRX?

Do analysts prefer NMRA or PCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools